MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Operating Income 2011-2026 | ADMP
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.1 M | -32.1 M | -36.3 M | -29.4 M | -39.5 M | -24.8 M | -25.2 M | -13.9 M | -9.72 M | -3.22 M | -4.82 M | -6.24 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.22 M | -39.5 M | -20.8 M |
Quarterly Operating Income Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.27 M | -6.43 M | - | -4.63 M | -8.18 M | -7.91 M | - | -10.2 M | -7.65 M | -6.22 M | - | -5.5 M | -11.2 M | -10.3 M | - | -7.01 M | -7.75 M | -8.94 M | - | -8.91 M | -9.67 M | -7.61 M | - | -5.8 M | -4.92 M | -5.71 M | - | -6.58 M | -7.43 M | -6.02 M | - | -3.31 M | -3.53 M | -4.15 M | - | -1.94 M | -2.75 M | -1.71 M | -984 K | -957 K | -1.7 M | - | -748 K | -2.32 M | -1.58 M | - | -989 K | -3.68 M | -2.69 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -748 K | -11.2 M | -5.29 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.41 | -1.02 % | $ 118 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
30.5 M | $ 36.73 | 3.67 % | $ 1.35 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.14 | 2.28 % | $ 44.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.35 | 1.71 % | $ 1.95 B | Canada |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.43 | 1.78 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.04 | 4.83 % | $ 112 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.39 | 5.75 % | $ 315 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 23.25 | 3.2 % | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.09 | 0.25 % | $ 264 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.39 | 6.88 % | $ 430 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.39 | 1.46 % | $ 402 M | Canada |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.01 | 3.85 % | $ 277 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.36 | 3.82 % | $ 3.37 M | Canada |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 1.0 | 3.87 % | $ 49.9 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 8.02 | 3.62 % | $ 702 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.29 | 3.62 % | $ 2.84 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.75 | 4.49 % | $ 4.17 B | Canada |
 |
Veru
VERU
|
-36.9 M | $ 2.55 | 2.82 % | $ 344 M | USA |
 |
Viatris
VTRS
|
766 M | $ 13.57 | 3.12 % | $ 16.3 B | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.7 | -0.19 % | $ 3.02 M | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.94 | -1.12 % | $ 33.8 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.62 | 1.57 % | $ 2.66 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.05 | 1.49 % | $ 23.7 M | USA |